Institution Directory

Clinical trials at Stanford Medicine

Sites in Stanford & Palo Alto, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 11:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1355

Shown on this page

Current sort

Stored official records

Conditions: Postoperative Respiratory Failure, Ventilatory Depression
Interventions: Oxygen Gas for Inhalation; Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Aortic Stenosis, Severe
Interventions: SAPIEN X4 THV, SAPIEN X4S; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: Not listed
Enrollment: 1,234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2037
U.S. locations: 58
States / cities: La Jolla, California • Los Angeles, California • Newport Beach, California + 44 more

Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Interventions: Zidesamtinib (NVL-520); Drug
Lead sponsor: Nuvalent Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 20
States / cities: Orange, California • Palo Alto, California • Sacramento, California + 15 more

Conditions: SMA, Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III
Interventions: Onasemnogene Abeparvovec-xioi; Biological
Lead sponsor: Novartis Gene Therapies; Industry
Eligibility: Not listed
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2035
U.S. locations: 18
States / cities: Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 14 more

Conditions: Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma
Interventions: Involved-site radiation therapy, Stem cell mobilization and collection, gemcitabine, liposomal doxorubicin, pembrolizumab, vinorelbine; Radiation · Procedure · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 257 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 10
States / cities: Duarte, California • Stanford, California • Miami, Florida + 7 more

Conditions: PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma
Interventions: daraxonrasib; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 43
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 33 more

Conditions: Radiation-Induced Xerostomia and Hyposalivation
Interventions: Placebo, RXRG001; Biological
Lead sponsor: RiboX Therapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Palo Alto, California • Iowa City, Iowa • Baltimore, Maryland + 2 more

Conditions: Mantle Cell Lymphoma
Interventions: Brexucabtagene Autoleucel, Pirtobrutinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Stanford, California • Miami, Florida • Tampa, Florida

Conditions: Lung Transplant Rejection
Interventions: Azithromycin, Belumosudil, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more

Conditions: Myotonic Dystrophy Type 1 (DM1)
Interventions: DYNE-101, Placebo; Drug
Lead sponsor: Dyne Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 8
States / cities: Stanford, California • Gainesville, Florida • Indianapolis, Indiana + 5 more

Conditions: Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Suprasellar Germ Cell Tumor
Interventions: Biospecimen Collection, Carboplatin, Etoposide, Filgrastim, Ifosfamide, Magnetic Resonance Imaging, Mesna, Pegfilgrastim, Peripheral Blood Stem Cell Transplantation, Questionnaire Administration, Radiation Therapy, Second-Look Surgery, Thiotepa; Procedure · Drug · Biological + 2 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 29 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 152
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 120 more

Conditions: Atherosclerosis, Coronary Artery Disease
Interventions: YN001/Placebo 0mg, YN001/Placebo 20mg, YN001/Placebo 40mg; Drug
Lead sponsor: Beijing Inno Medicine Co., Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 22
States / cities: Huntsville, Alabama • Covina, California • Lincoln, California + 19 more

About this Stanford Medicine institution page

What this page lists: ClinicalTrials.gov records that list Stanford Medicine in Stanford & Palo Alto, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Stanford Medicine

Filter and sort this campus

Stored official records

The Effect of Hyperoxia on Ventilation During Recovery From General Anesthesia

ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis

About this Stanford Medicine institution page